Drug Profile
DNS 006
Alternative Names: DNS-006; glycine transporter 1 inhibitors - Dart NeurosciencesLatest Information Update: 01 Dec 2023
Price :
$50
*
At a glance
- Originator Helicon Therapeutics
- Developer Dart NeuroScience
- Class Nootropics
- Mechanism of Action Glycine transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cognition disorders
Most Recent Events
- 09 Oct 2023 DNS 006 is still in preclinical stage for cognition disorders in USA (Dart Neurosciences pipeline, October 2023)
- 24 Feb 2023 Discontinued - Preclinical for Cognition disorders in USA (unspecified route) (Dart NeuroScience pipeline, February 2023)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Cognition-disorders in USA